TSHA Taysha Gene Therapies, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1806310 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.1%
TTM net income YoY-56.1%
TTM EPS YoY-27.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,935.4%
Net margin-2,844.6%
FCF margin-2,582.6%
EBITDA margin-2,913.6%
Returns
ROE-54.2%
ROA-41.5%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.13x
Current ratio18.56x
Interest coverage-5,193.77x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue13.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $9.77M | $8.33M |
| R&D expense | $86.40M | $66.00M |
| SG&A expense | $33.87M | $28.95M |
| Operating income | -$110.50M | -$91.46M |
| Interest expense | $63,000 | $102,000 |
| Income tax | $0 | $0 |
| Net income | -$109.00M | -$89.30M |
| EBITDA | -$109.35M | -$90.21M |
| EPS (basic) | -0.34 | -0.36 |
| EPS (diluted) | -0.34 | -0.36 |
| Weighted avg. shares (diluted) | 319.71M | 250.13M |
| Balance sheet | ||
| Cash & equivalents | $319.77M | $139.04M |
| Current assets | $324.65M | $142.13M |
| PP&E, net | $6.74M | $7.49M |
| Total assets | $343.32M | $160.36M |
| Current liabilities | $26.55M | $26.23M |
| Long-term debt | $50.11M | $43.94M |
| Total debt | $50.11M | $43.94M |
| Total liabilities | $96.38M | $88.84M |
| Shareholders' equity | $246.94M | $71.53M |
| Net debt | -$269.66M | -$95.09M |
| Shares outstanding | 285.05M | 204.94M |
| Cash flow statement | ||
| Operating cash flow | -$93.09M | -$81.22M |
| Capital expenditure | $738,000 | $374,000 |
| Free cash flow | -$93.83M | -$81.60M |
| Investing cash flow | -$604,000 | -$363,000 |
| Financing cash flow | $274.59M | $76.68M |
| Depreciation & amortization | $1.15M | $1.25M |
| Stock-based compensation | $13.30M | $13.10M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.